期刊文献+

多靶点酪氨酸激酶抑制剂的研究进展

Progress in the Research of Multi-Target Tyrosine Kinase Inhibitors
暂未订购
导出
摘要 多靶点酪氨酸激酶抑制剂的研究已经成为近年来抗肿瘤药物研究的新趋势。本文整合国内外相关文献,综述了近年来各课题组对不同结构的酪氨酸激酶抑制剂及抗肿瘤活性的研究进展,以期为酪氨酸激酶抑制剂的研究与开发提供参考。 The study on multi-targeted tyrosine kinase inhibitors has become a new trend in researches on antitumor drugs in recent years.In order to offer reference to the research and development of tyrosine kinase inhibitors,this review introduced the research results of tyrosine kinase inhibitors with different structures and antitumor activity by summarizing related literature,at home and abroad.
作者 刘丹 李雪 张毅 彭鹏辉 Dan Liu;Xue Li;Yi Zhang;Penghui Peng(College of Pharmaceutical and Biological Engineering,Shenyang University of Chemical Technology,Shenyang Liaoning)
机构地区 沈阳化工大学
出处 《药物化学》 2016年第4期42-54,共13页 Hans Journal of Medicinal Chemistry
关键词 多靶点 酪氨酸激酶抑制剂 抗肿瘤 Multi-Target Tyrosine Kinase Inhibitor Antitumor
  • 相关文献

参考文献18

二级参考文献339

  • 1任欢,李殿俊,Rainov NG.STI571对恶性多发性神经胶质母细胞瘤(GBM)的体外抑瘤作用[J].中国肿瘤临床,2004,31(15):856-859. 被引量:3
  • 2Toufeng Jin,Hajime Nakatani,Takahiro Taguchi,Takumi Nakano,Takehiro Okabayashi,Takeki Sugimoto,Michiya Kobayashi,Keijiro Araki.STI571 (Glivec) suppresses the expression of vascular endothelial growth factor in the gastrointestinal stromal tumor cell line,GIST-T1[J].World Journal of Gastroenterology,2006,12(5):703-708. 被引量:14
  • 3贡联兵.酪氨酸激酶抑制剂的进展与评价[J].中国医院用药评价与分析,2006,6(6):329-332. 被引量:10
  • 4Jimeno A,Hidalgo M.Multitargeted therapy:can promiscuity be praised in an era of political correctness?[J].Crit Rev Oncol Hematol,2006,59(2):150-158.
  • 5De Jonge MJ,Verweij J.Multiple targeted tyrosine kinase inhibition in the clinic:all for one or one for all?[J].Eur J Cancer,2006,42(10):1351-1356.
  • 6Keith CT,Borisy AA,Stockwell BR.Multicomponent therapeutics for networked systems[J].Nat Rev Drug Discov,2005,4(1):71-78.
  • 7Arora A,Scholar EM.Role of tyrosine kinase inhibitors in cancer therapy[J].J Pharmacol Exp Ther,2005,315(3):971-979.
  • 8Blume-Jensen P,Hunter T.Oncogenic kinase signalling[J].Nature,2001,411(6835):355-365.
  • 9Konecny GE,Pegram MD,Venkatesan N,et al.Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells[J].Cancer Res,2006,66(3):1630-1639.
  • 10Burris HA,Hurwitz HI,Dees EC,et al.Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinib (GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas[J].J Clin Oncol,2005,23(23):5305-5313.

共引文献160

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部